radiotherapy

PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...

Houston, Texas, August 14, 2026 Cerenome, Inc. reported continued progress across its integrated central nervous system (CNS) oncology platform,...

CULVER CITY, Calif., July 28, 2026 Avenda Health announced that its FDA-cleared Unfold AI platform is now being used...

SYDNEY, Australia – July 24, 2026 Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO...

MALLORCA, Spain, July 23, 2026 Laminar Pharmaceuticals S.A. has announced the successful completion of patient recruitment for the CLINGLIO...

JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...

JERUSALEM, Israel – May 5, 2026 Alpha Tau Medical Ltd. has announced that new clinical data evaluating Alpha DaRT®...

PARIS, France and CAMBRIDGE, Mass., United States – May 4, 2026 Nanobiotix has announced FDA acceptance of a protocol...

Nanobiotix S.A. (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches for cancer and other serious...